To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.
Latest Action
Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
Official Summary
Nucleic Acid Standards for Biosecurity Act This bill explicitly requires the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis. Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), carry genetic information within cells. Nucleic acid synthesis is the process of designing and creating custom nucleic acids; it is used in the development of medications and agricultural products. However, this technology also poses a risk of misuse (e.g., the intentional or unintentional creation of dangerous biological agents). The bill requires NIST to carry out measurement research to support the development and improvement of biosecurity best practices and technical standards related to nucleic acid synthesis. This effort must address specified topics including nucleic acid synthesis screening, operational security, and conformity assessment. (A 2023 executive order titled Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence directed NIST to develop and refine similar specifications and best practices for use by synthetic nucleic acid providers. NIST's work on this topic is ongoing.) In carrying out this effort, NIST must convene stakeholders to develop and periodically update consensus priorities and best practices for synthetic nucleic acid screening mechanisms. Within a specified period, NIST must submit a summary of the stakeholder group’s findings to Congress. NIST must also take steps to advance risk management best practices and technical standards for engineering biology and biomanufacturing, including with respect to risks associated with the use of artificial intelligence.
GovScope Watchdog™
AI Government Intelligence™The Nucleic Acid Standards for Biosecurity Act mandates the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis, a process critical to biotechnology and medicine. The bill directs NIST to conduct measurement research and convene stakeholders to develop consensus priorities and best practices for screening synthetic nucleic acids, operational security, and conformity assessment. It also requires NIST to advance risk management standards related to engineering biology and biomanufacturing, including risks associated with artificial intelligence. The bill builds on ongoing NIST efforts and a 2023 executive order focused on safe and secure development of synthetic nucleic acids.
This bill formalizes and expands NIST's role in developing standards and best practices to enhance biosecurity in nucleic acid synthesis and related biotechnologies.
- Requires NIST to conduct measurement research supporting biosecurity best practices and technical standards for nucleic acid synthesis.
- Mandates stakeholder engagement to develop and update consensus priorities and best practices for synthetic nucleic acid screening.
- Directs NIST to advance risk management standards for engineering biology and biomanufacturing, including AI-related risks.
['National Institute of Standards and Technology (NIST)', 'Biotechnology and biomanufacturing industries', 'Synthetic nucleic acid providers', 'Public health and biosecurity agencies', 'Researchers and developers in genetic engineering and synthetic biology']
['Implementation complexity in coordinating diverse stakeholders and updating standards periodically.', 'Potential costs associated with research, stakeholder engagement, and standard development.', 'Oversight and enforcement mechanisms for adherence to developed standards are not specified.', 'Scope of authority for NIST in regulating or influencing private sector practices may require clarification.']
The bill amends the Research and Development, Competition, and Innovation Act to address emerging biosecurity challenges related to nucleic acid synthesis. It aligns with a 2023 executive order directing NIST to develop standards for synthetic nucleic acids and reflects ongoing federal efforts to manage risks associated with biotechnology and artificial intelligence. The bill is currently in process, having passed the House and been referred to the Senate Committee on Commerce, Science, and Transportation.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Improved biosecurity standards may enhance public trust in biotechnology and synthetic biology sectors.', 'Advancements in risk management for AI in biomanufacturing could influence broader AI governance frameworks.', 'Standardization efforts may facilitate international collaboration or influence global norms in synthetic nucleic acid synthesis.']
The bill's transparency is supported by the requirement for NIST to submit summaries of stakeholder findings to Congress. However, the absence of detailed enforcement mechanisms and funding specifics may warrant monitoring to assess how effectively the standards are implemented and maintained. Oversight of NIST's coordination with private sector entities and the impact on innovation and security balance should be tracked.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.